Metastatic Kidney Cancer Treatment
When kidney cancer, sometimes called renal cancer, spreads to another part of the body, it is considered metastatic kidney cancer. Metastases may develop in multiple organs and can show up as multiple tumors or lesions. Kidney cancer metastasized to the bones or lungs develops in 50 percent of people who have a metastasis. Kidney cancer metastasis to the brain occurs in about 20 percent of cases.
As soon as you are diagnosed with metastatic kidney cancer, ask your physician these three questions.
The UF Metastatic Cancer Program’s integrated strategy offers comprehensive treatment through an aggressive new approach, working collaboratively with a patient’s existing medical oncologist and in tandem with standard chemotherapy.
The best chance at managing metastatic kidney cancer is to act at the first sign of symptoms or immediately upon diagnosis. The UF Metastatic Cancer Program treats patients who have 10 or fewer new lesions and whose primary tumor is controlled or inactive.
Our method for treating cancer uses a targeted type of radiation called stereotactic body radiation therapy (SBRT) to pinpoint the metastatic lesions and destroy them on contact. Because SBRT has the ability to eliminate tumors with less damage to healthy tissue and a more comfortable recovery time than other methods for removal, it is particularly beneficial for patients who are not candidates for surgery.
If new tumors develop later and are identified early, SBRT is an effective method for elimination.
Because every patient is different, our multidisciplinary team of physicians carefully reviews each case to determine the most effective treatment plan.
Additional therapies at the UF Metastatic Cancer Program include:
- Tumor immune therapy
- Tumor vaccine therapy
- Tumor anti-vascular therapy
- Interventional pulmonology
- Interventional radiology procedures